Posts Categorized: Drug Pricing

Kenya society unites to take on Big Pharma

The pharmaceutical industry has been in the spotlight for some time for its inability to provide reasonably priced medicine to those most in need, particularly in developing and least-developed countries. Making matters worse is a complex web of governmental and trade regulations that make progress painfully slow when lives are lost daily because patients cannot…

AHF: Grandes Farmacêuticas Devem Reduzir Seus Preços Exorbitantes para Pessoas Vivendo com Hepatite C

Às vésperas da Cúpula Mundial de Hepatites no Brasil, ativistas exigem das companhias farmacêuticas preços menores nas drogas para hepatites, visando facilitar o alcance das metas de tratamento para 71 milhões de pessoas vivendo com Hepatite C ao redor do mundo. São Paulo, Brasil (31 de outubro de 2017) às vésperas da Cúpula Mundial de…

AHF: Farmacéuticas deben recortar precios exorbitantes del Sofosbuvir para pacientes con Hepatitis C

Previo a la Cumbre Mundial de Hepatitis en Brasil, activistas llaman a la industria farmacéutica a que disminuyan los precios de medicamentos para hepatitis y lograr las metas de tratamiento a 71 millones de personas conHepatitis C. Sao Paulo, Brazil (Octubre 31, 2017) Previo a la Cumbre Mundial de Hepatitis en Sao Paulo, AIDS Healthcare…

Legislative Update: U.S. House Energy and Commerce Subcommittee on Oversight and Investigations Holds Hearing on 340B Drug Pricing Program

The U.S. House of Representatives Energy and Commerce Subcommittee on Oversight and Investigations held a hearing on Wednesday, October 11 entitled, “Examining how covered entities utilize the 340B drug pricing program.” Speakers called before the committee represented a range of health care providers, including Ryan White Grantees, similar to AIDS Healthcare Foundation. “While the official…

As Patent Expires, AHF Calls on Gilead for 90% Price Reduction on Tenofovir-based Drugs, Including Truvada

Ethically challenged drug company has made billions off the drug since its initial FDA approval while it simultaneously sought to ‘evergreen’ and manipulate patent extension process LOS ANGELES (October 17, 2017) AIDS Healthcare Foundation (AHF), the largest global AIDS organization and a vocal critic of runaway drug pricing and drug profiteering today called on Gilead…

AHF: Gilead Says it “Had No Duty to Develop” Less Harmful AIDS Drug in Legal Motion on Patent Lawsuit

In January, AHF filed a federal lawsuit against Gilead Sciences, Inc. and two other defendants alleging drug patent manipulation and anti-trust claims regarding Genvoya, Gilead’s new four-in-one Fixed Dose Combination (FDC) to treat HIV/AIDS patients. Gilead unsuccessfully sought US patent extension on Stribild, its similar but earlier FDC that includes a form of Tenofovir, the…

Husted Transmits Ohio Drug Pricing Initiative to General Assembly; Had No Legal Standing for One Month Delay

Month-long delay by Ohio Secretary of State Jon Husted was an illegal political move by Husted at bidding of a pharma law firm that contributed over $44,000 to his elections over the years. COLUMBUS, OH (February 4, 2016) Advocates from AIDS Healthcare Foundation (AHF) and members of Ohioans for Fair Drug Prices today welcomed news…